Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery.
Current anti-influenza virus drugs target two viral proteins and induce a selective pressure for the generation of drug resistant variants. This stresses the need for additional therapeutic strategies including drug targeting of cellular factors that are essential for viral replication. Reverse genetics approaches can be used to identify these factors and recently six independent genomic initiatives have led to the identification of 925 host factors that are essential for the replication of influenza viruses. Here we report a meta-analysis of this dataset, first revealing that these screens are poorly overlapping at the gene level. However, a strong convergence was observed at the level of biological processes which was further supported by an interactomic analysis showing a high interconnectivity of the essential host factors in the human protein network. Plugging virus-host protein interaction data on this dataset reveals a significant targeting of these factors by viral proteins, further validating the cellular targets. Combining this information, the first drug-influenza virus target network was constructed by retrieving from DrugBank 298 molecules interacting with 100 essential host factors. Of these, 204 are FDA-approved offering interesting potential for rapid drug repositioning in the treatment of flu.
Université de Lyon, France.
Benoît
B
de Chassey
Laurène
L
Meyniel-Schicklin
Anne
A
Aublin-Gex
Patrice
P
André
Vincent
V
Lotteau
D000998:Antiviral Agents / Q000494:pharmacology; D055808:Drug Discovery; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy / Q000821:virology; D009975:Orthomyxoviridae / Q000235:genetics / Q000502:physiology*; D059386:Reverse Genetics / Q000379:methods*; D014764:Viral Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D014779:Virus Replication
D000998:Antiviral Agents; D014764:Viral Proteins